Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company dedicated to discovering, developing and commercializing scientifically advanced therapeutic products that are focused on helping patients suffering from central nervous system and respiratory disorders, as well as other illnesses.
A wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., Sunovion was formed following the merger of Sumitomo Dainippon Pharma's two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc. The company name, which is representative of the life-affirming energy of the sun and the power of innovation, reflects Sunovion's portfolio of currently marketed pharmaceutical products and pipeline candidates; and serves to emphasize the company's ongoing commitment to improve the lives of patients everywhere.
|4/14/15||Sunovion Pharmaceuticals Inc. to Present Data on Aptiom® (eslicarbazepine acetate) at 67th American Academy of Neurology Annual Meeting|
|3/31/15||New Post-hoc Analyses Extend Understanding of the Efficacy and Safety of Lurasidone in the Treatment of Schizophrenia|
|3/30/15||Sunovion Pharmaceuticals Europe Ltd. to Present New Data on LATUDA® ▼ (lurasidone) at the 23rd European Congress of Psychiatry|
|2/25/15||Sunovion Pharmaceuticals Inc. Announces Initiation of Phase 3 Clinical Trial Program for SUN-101/eFlow® (Glycopyrrolate) in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)|
|1/14/15||Sunovion Pharmaceuticals Inc. Files Patent Infringement Lawsuits Regarding Latuda®|
|1/7/15||Sunovion Pharmaceuticals Inc. Announces FDA Acceptance for Review of Supplemental New Drug Application for the Use of Aptiom® (eslicarbazepine acetate) as Monotherapy Treatment for Partial Onset Seizures|